Dimitrios Alexopoulos

List of Publications by Year in descending order

45 papers	4,917 citations	471061 17 h-index	329751 37 g-index
46 all docs	46 docs citations	46 times ranked	6946 citing authors

#	Article	IF	Citations
1	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	1.0	2,246
2	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	1.2	807
3	Updated Expert Consensus Statement on Platelet Function and Genetic Testing forÂGuiding P2Y12 Receptor Inhibitor Treatment in Percutaneous CoronaryÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	1.1	366
4	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. JAMA Network Open, 2020, 3, e2013136.	2.8	344
5	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptorâ€“Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
6	Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction. Circulation, 2015, 132, 1395-1403.	1.6	208
7	Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel. JACC: Cardiovascular Interventions, 2011, 4, 403-410.	1.1	113
8	In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Prevalence, predictors and short-term outcome. American Heart Journal, 2014, 167, 68-76.e2.	1.2	70
9	Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. American Heart Journal, 2011, 162, 733-739.	1.2	60
10	Differential Effect of Ticagrelor Versus Prasugrel on Coronary Blood Flow Velocity in Patients With Nonâ€“ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 277-283.	1.4	59
11	Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clinical Research in Cardiology, 2019, 108, 1093-1101.	1.5	41
12	Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. European Heart Journal, 2021, 42, 4536-4549.	1.0	37
13	P2Y ₁₂ Receptor Antagonists and Morphine. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	32
14	Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2018, 32, 287-294.	1.3	31
15	Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study. Basic Research in Cardiology, 2021, 116, 9.	2.5	24
16	Contraindications/Special Warnings and Precautions for Use of Contemporary Oral Antiplatelet Treatment in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Circulation Journal, 2014, 78, 180-187.	0.7	18
17	Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 139-148.	1.4	18
18	Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 152-157.	1.4	16

#	Article	IF	Citations
19	Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110295.	1.5	12
20	Î²-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease. Journal of Thrombosis and Thrombolysis, 2020, 49, 365-376.	1.0	11
21	Does Ticagrelor Improve Endothelial Function?. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 11-17.	1.0	10
22	Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation. Current Vascular Pharmacology, 2016, 14, 487-491.	0.8	10
23	Long-Term P2Y12-Receptor Antagonists inÂPost-Myocardial Infarction Patients. Journal of the American College of Cardiology, 2016, 68, 1223-1232.	1.2	9
24	Dyspnea in patients treated with P2Y₁₂ receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry. Platelets, 2017, 28, 691-697.	1.1	9
25	Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease. Hellenic Journal of Cardiology, 2018, 59, 338-343.	0.4	9
26	Differential effects of heat-not-burn and conventional cigarettes on coronary flow, myocardial and vascular function. Scientific Reports, 2021, 11, 11808.	1.6	9
27	Tailoring Dual Antiplatelet Therapy for the Complex PCI Patient: Current Status and Perspectives. Cardiovascular Drugs and Therapy, 2020, 34, 697-706.	1.3	7
28	Low-Dose Ticagrelor VersusÂClopidogrel in PatientsÂWith Prior MyocardialÂInfarction. Journal of the American College of Cardiology, 2017, 70, 2091-2092.	1.2	6
29	Temporal changes of noninvasive electrocardiographic risk factors for sudden cardiac death in postâ€myocardial infarction patients with preserved ejection fraction: Insights from the PRESERVEâ€EF study. Annals of Noninvasive Electrocardiology, 2020, 25, e12701.	0.5	6
30	Global Longitudinal Strain of the Systemic Ventricle Is Correlated with Plasma Galectin-3 and Predicts Major Cardiovascular Events in Adult Patients with Congenital Heart Disease. Medicina (Lithuania), 2020, 56, 305.	0.8	6
31	Pleiotropic Effects of Platelet P2Y₁₂ Receptor Inhibitors: Fact or Fiction?. Current Pharmaceutical Design, 2014, 20, 4597-4604.	0.9	4
32	P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes. Expert Review of Cardiovascular Therapy, 2019, 17, 717-727.	0.6	4
33	De-Escalation of Treatment With Oral P2Y12 Receptor Inhibitors: Current Status and Perspectives. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 304-314.	1.0	4
34	Platelets from patients with myocardial infarction can activate T cells. Haematologica, 2020, 106, 288-290.	1.7	3
35	Not-high before-treatment platelet reactivity in patients with STEMI: prevalence, clinical characteristics, response to therapy and outcomes. Platelets, 2022, 33, 390-397.	1.1	3
36	Left Main Coronary Interventions: A Practical Guide. Cardiovascular Revascularization Medicine, 2020, 21, 1596-1605.	0.3	2

#	Article	IF	Citations
37	Use of Optical Coherence Tomography in MI with Non-obstructive Coronary Arteries. Interventional Cardiology Review, 0, 17, .	0.7	2
38	Antithrombotic Therapy in Chronic Total Occlusion Interventions. US Cardiology Review, 0, 15, .	0.5	1
39	Platelet Function Testing and Genotyping for Tailoring Treatment in Complex PCI Patients. US Cardiology Review, 0, 15, .	0.5	1
40	Delayed onset of novel P2Y 12 receptor antagonists action post fibrinolysis. International Journal of Cardiology, 2017, 234, 131.	0.8	0
41	Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. Thrombosis and Haemostasis, 2018, 118, 852-863.	1.8	0
42	Editorial: The Ongoing Quest for Mono-Antiplatelet Therapy Post-PCI. Cardiovascular Revascularization Medicine, 2020, 21, 790-791.	0.3	0
43	Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation. US Cardiology Review, 0, 15, .	0.5	0
44	Left Main Disease and Bifurcation Percutaneous Coronary Intervention: Focus on Antithrombotic Therapy. US Cardiology Review, 0, 15, .	0.5	0
45	Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment. US Cardiology Review, 0, 15, .	0.5	0